Investigational Drug Information for AZD4831
✉ Email this page to a colleague
What is the development status for investigational drug AZD4831?
AZD4831 is an investigational drug.
There have been 14 clinical trials for AZD4831.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 30th 2021.
The most common disease conditions in clinical trials are Heart Failure, Cardiovascular Diseases, and Fatty Liver. The leading clinical trial sponsors are AstraZeneca, Parexel, and Mayo Clinic.
Summary for AZD4831
| US Patents | 0 |
| International Patents | 44 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-06-30) |
| Vendors | 17 |
Recent Clinical Trials for AZD4831
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment | AstraZeneca | Phase 1 |
| An Efficacy and Safety Study of AZD4831 (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. | AstraZeneca | Phase 2 |
| A Study in Participants With Non-cirrhotic NASH With Fibrosis | AstraZeneca | Phase 2 |
Clinical Trial Summary for AZD4831
Top disease conditions for AZD4831
Top clinical trial sponsors for AZD4831
US Patents for AZD4831
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD4831
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD4831 | Argentina | AR102863 | 2034-12-01 | ⤷ Subscribe |
| AZD4831 | Australia | AU2015357290 | 2034-12-01 | ⤷ Subscribe |
| AZD4831 | Brazil | BR112017011124 | 2034-12-01 | ⤷ Subscribe |
| AZD4831 | Canada | CA2968449 | 2034-12-01 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
